Sign In
Buy SRPT
$14.86
-0.700 (-4.50%)
At Close: Jul 31, 2026
Sarepta's Duchenne gene therapy helps maintain motor function, three-year data shows
08:10am, Monday, 26'th Jan 2026
Sarepta Therapeutics' gene therapy for a progressive muscle‑wasting disorder showed sustained benefit in patients' ability to control and coordinate movement, according to three‑year data from a l
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced positive topline three-year functional results
Sarepta Therapeutics shares rise on positive Duchenne gene therapy data
05:38am, Monday, 26'th Jan 2026
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares moved higher in early trade on Monday as it reported positive topline three-year results from its Phase 3...
Stock Market Today: Dow Jones, S&P 500 Futures Slip As Investors Brace For Mega-Cap Earnings—Brand Engagement, Nucor In Focus
05:36am, Monday, 26'th Jan 2026
U.S. stock futures dropped on Monday following Friday's mixed close. Futures of major benchmark indices were lower.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Monday, Jan. 26, 2026, at 8:30 am Easte
2 Beaten-Down Stocks That Could Sink Even More in 2026
10:30pm, Wednesday, 21'st Jan 2026
Sarepta Therapeutics' drug safety issues are overshadowing its innovative platform. Teladoc Health's financial results continue to worsen, and the stock looks unlikely to recover.
Sarepta Therapeutics, Inc. $SRPT Stock Holdings Boosted by State of Alaska Department of Revenue
05:26am, Monday, 19'th Jan 2026
State of Alaska Department of Revenue increased its position in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) by 343.7% during the third quarter, according to the company in its most recent 13F filing wit
Sarepta Therapeutics: Is Elevidys A Bust?
09:25am, Friday, 16'th Jan 2026
Sarepta Therapeutics remains highly volatile as ELEVIDYS sales drive sentiment, with Q4 revenue missing expectations and safety concerns lingering. Despite fading ELEVIDYS sales, SRPT management reite
Market Today: Banks, Big Tech, Biopharma and Energy Move on Policy and Deals
05:34pm, Monday, 12'th Jan 2026
Guru Stock PicksJerome Dodson has made the following transactions:Reduce in ORLY by 3%Sold out in BLDRAdd in NTRA by 2.49%New position in INSMTweedy Browne Inte
Sarepta Therapeutics, Inc. (SRPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
02:36pm, Monday, 12'th Jan 2026
Sarepta Therapeutics, Inc. (SRPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues
11:58am, Monday, 12'th Jan 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reports preliminary* fourth quarter and full-year 2025 ne
Johnson Fistel Investigates Sarepta Therapeutics, Inc. (SRPT) Directors for Potential Breaches of Fiduciary Duty
09:30am, Monday, 12'th Jan 2026
San Diego, California--(Newsfile Corp. - January 12, 2026) - Shareholder rights law firm Johnson Fistel, PLLP is investigating potential shareholder derivative claims on behalf of Sarepta Therapeutics
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Recommendation of “Hold” from Analysts
01:24am, Sunday, 11'th Jan 2026
Shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT - Get Free Report) have been assigned an average rating of "Hold" from the thirty brokerages that are currently covering the stock, Marketbeat Rating
Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington's Disease
08:30am, Wednesday, 07'th Jan 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the submission of its clinical trial applicatio
Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
08:30am, Monday, 05'th Jan 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 44th
